Uni-Bio Science Group Forges Strategic Alliance with LUQA

HONG KONG, CHINA - Media OutReach - 14 November 2016 - Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has today announced that it has established a strategic partnership with Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. ("LUQA"), a China-focused specialty pharmaceutical company, to conduct co-promotion or/ and co-marketing of dermatology drugs in Mainland China, enabling the Group to immediately expand its income stream and generate cash flow.

Mr. Kingsley Leung, Executive Director of Uni-Bio Science Group Limited (left) and Mr. Robert Braithwaite, Chief Executive Officer of Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. (right) sign an agreement to establish a strategic partnership of the two companies.

Under the terms of the strategic alliance agreement, products for co-promotion or/ and co-marketing cover drugs or medical devices for the treatment of dermatological disorders, including but not limited to Uni-Bio Science's and LUQA's current and future innovations in the dermatology field. More specifically, under the terms of the three-year promotion agreement with an option to renew for two additional years, Uni-Bio Science will co-promoteselected products in hospitals or qualified institutions, drug stores and retail channels in certain territories. Uni-Bio Science will additionally support LUQA with market access in the territories, including provincial and national reimbursement expansion of products under collaboration.  

Mr. Kingsley Leung, Executive Director of Uni-Bio Science said, "Promptly following our strategic alliance with China Resources Zizhu forged in June, I am very excited to announce this strategic partnership with LUQA, which not only reinforces our partnership model, but also enables us to accelerate the penetration of drugs or medical devices of our current product lines for dermatological treatment -- a major therapeutic area of the Group -- in Mainland China. LUQA has a very interesting product portfolio in dermatology, especially in the aesthetics space. A number of these productscan be co-promoted with our GeneTime^® to provide a comprehensive solution for our patients in terms of wound and scar management. Leveraging our success with GeneTime^® in China, we are confident of effectively expanding the footprint of LUQA's products in the market. In this way we can create a win-win situation for both parties and cement our leadership position in the dermatology market." 

Mr. Robert Braithwaite, Chief Executive Officer of LUQA said, "This collaboration enables us to work together to bring forward innovative medical solutions demonstrated to improve outcomes and quality of life to patients in China. Uni-Bio Science has demonstrated over the years the strength of their commercial teams in accessing and educating physicians.We believe this co-promotion agreement will drive value for LUQA and reinforce our market leadership position in innovative skin solutions for medical and aesthetic dermatology. This cooperation is synergistic with our group's existing commercial efforts for our products in the hospital market and will enable us to further strengthen our commercial capabilities as we prepare to market additional medical and aesthetic products."

Apart from this latest cooperation forged with LUQA, in June 2016, the Group had signed a strategic alliance agreement with China Resources Zizhu Pharmaceutical Co., Limited to distribute and promote GeneSoft^® in Mainland China for a minimum of five years. In addition, the Group has partnered heavily in the past two years with both foreign and domestic companies to bring a number of important therapies in the ophthalmology and diabetes space to patients. Going forward, the Group is keeping a close eye on the opportunities of in-licensing or acquiring products or technologies that complement its pipeline products, including but not limited to Uni-E4 for the treatment of Type-2 diabetes. With a clear development roadmap, Uni-Bio is well on the way to continue "Leading Genuine Innovation" and maintain rapid growth in the market.

Image

Mr. Kingsley Leung, Executive Director of Uni-Bio Science Group Limited (left) and Mr. Robert Braithwaite, Chief Executive Officer of Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. (right) sign an agreement to establish a strategic partnership of the two companies.

http://release.media-outreach.com/i/Download/6113

Company Logo

http://release.media-outreach.com/i/Download/6112

About Uni-Bio Science Group Limited (SEHK: 0690)

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

About Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd.

Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. is a China-focused company. It acquires, develops and commercialises innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. Luqa aims to become a leader in specialty care segments in China, Hong Kong and Macau.